- Home
- ACM vs INCY Comparison
ACM vs INCY Comparison
Compare ACM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- INCY
- Stock Information
- Founded
- ACM 1980
- INCY 1991
- Country
- ACM United States
- INCY United States
- Employees
- ACM N/A
- INCY N/A
- Industry
- ACM Military/Government/Technical
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ACM Consumer Discretionary
- INCY Health Care
- Exchange
- ACM Nasdaq
- INCY Nasdaq
- Market Cap
- ACM 14.7B
- INCY 13.4B
- IPO Year
- ACM 2007
- INCY 1993
- Fundamental
- Price
- ACM $115.08
- INCY $68.59
- Analyst Decision
- ACM Strong Buy
- INCY Hold
- Analyst Count
- ACM 8
- INCY 20
- Target Price
- ACM $119.88
- INCY $73.81
- AVG Volume (30 Days)
- ACM 969.4K
- INCY 1.8M
- Earning Date
- ACM 08-04-2025
- INCY 07-29-2025
- Dividend Yield
- ACM 0.91%
- INCY N/A
- EPS Growth
- ACM N/A
- INCY N/A
- EPS
- ACM 4.58
- INCY 0.10
- Revenue
- ACM $16,047,510,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- ACM $3.29
- INCY $13.48
- Revenue Next Year
- ACM $5.98
- INCY $10.35
- P/E Ratio
- ACM $25.07
- INCY $713.94
- Revenue Growth
- ACM 4.55
- INCY 17.13
- 52 Week Low
- ACM $84.33
- INCY $53.56
- 52 Week High
- ACM $118.56
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ACM 60.93
- INCY 52.44
- Support Level
- ACM $114.09
- INCY $66.85
- Resistance Level
- ACM $116.66
- INCY $70.62
- Average True Range (ATR)
- ACM 1.58
- INCY 1.85
- MACD
- ACM -0.04
- INCY -0.16
- Stochastic Oscillator
- ACM 70.38
- INCY 38.87
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.